Global Swine Mycoplasma Hyopneumoniae Live Vaccine Market Growth 2026-2032
The global Swine Mycoplasma Hyopneumoniae Live Vaccine market size is predicted to grow from US$ 28.17 million in 2025 to US$ 40.59 million in 2032; it is expected to grow at a CAGR of 5.3% from 2026 to 2032.
Swine Mycoplasma Hyopneumoniae Live Vaccine is a preventive veterinary biological product formulated with live attenuated Mycoplasma hyopneumoniae strains, mainly used for the prevention of swine enzootic pneumonia, mycoplasmal pneumonia and related respiratory diseases in pigs. Commercial products are generally supplied as freeze-dried live vaccines, and the currently verifiable mainstream strain routes mainly include Strain 168 and Strain RM48, with administration routes such as intrapulmonary injection, intrathoracic injection and intranasal inoculation depending on product design. Upstream inputs mainly include production seed strains, specialized culture media, serum or serum substitutes, lyoprotectants, stabilizers, cultivation and harvesting consumables, vials or plastic bottles, rubber stoppers, aluminum caps, labels, cold-chain packaging materials and GMP-compliant biological manufacturing facilities. Downstream customers primarily include large-scale swine farming groups, breeding farms, commercial pig farms, veterinary drug distributors, animal disease prevention service providers and field veterinary service channels. Under a strict live-vaccine ex-factory scope, global effective production capacity in 2025 is estimated at about 218 million doses, with sales volume of about 151 million doses and an average ex-factory price of about USD 0.19 per dose. As commercialized supply is mainly concentrated in China, mainstream overseas Mycoplasma hyopneumoniae vaccines that are inactivated vaccines or combination vaccines are not included in this statistical scope. The industry gross margin in 2025 is estimated at around 45%?60%.
The current market is mainly centered on domestic production and application in China, and it remains a specialized segment within the veterinary vaccine industry. Supply is relatively concentrated, and demand mainly comes from large-scale pig farms, breeding farms and production systems with higher requirements for respiratory disease control. Compared with conventional inactivated vaccines, live vaccines place greater emphasis on respiratory local immunity and integrated herd-level disease prevention, giving them a stable application base in selected high-health-status farms.
Future development will focus more on administration convenience, product stability and adaptability to large-scale farming operations. As farming enterprises continue to pursue standardized vaccination programs, lower handling stress, reduced labor intensity and more consistent immune outcomes, products with easier administration, better field usability and stronger freeze-dried stability are expected to gain greater acceptance. Competition will increasingly depend on strain resources, manufacturing quality, field application evidence, technical service capability and farm-level solution design.
Market growth is mainly driven by the continued expansion of large-scale pig farming, stronger demand for integrated respiratory disease control, reduced antibiotic use and greater attention to production efficiency. Mycoplasma hyopneumoniae infection can interact with other pathogens and affect herd performance through coughing, lung lesions, slower growth and weaker feed conversion efficiency, so preventive vaccination remains an important part of stable pig production. When farm profitability improves and disease-control budgets recover, the penetration of this product category is expected to increase.
The main restraints include competition from substitute products, higher requirements for standardized use, hog cycle volatility and cost pressure at the farm level. Inactivated vaccines and combination vaccines have strong advantages in program integration, ease of use and channel coverage, so some farms may prefer simpler integrated immunization solutions. In addition, live vaccines require stricter cold-chain storage, reconstitution and administration practices, and improper execution may affect immune performance and repeat purchasing; during periods of weak hog prices, non-mandatory vaccine spending is also more likely to be reduced.
LP Information, Inc. (LPI) ' newest research report, the ?Swine Mycoplasma Hyopneumoniae Live Vaccine Industry Forecast? looks at past sales and reviews total world Swine Mycoplasma Hyopneumoniae Live Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Swine Mycoplasma Hyopneumoniae Live Vaccine sales for 2026 through 2032. With Swine Mycoplasma Hyopneumoniae Live Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Swine Mycoplasma Hyopneumoniae Live Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Swine Mycoplasma Hyopneumoniae Live Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Swine Mycoplasma Hyopneumoniae Live Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Swine Mycoplasma Hyopneumoniae Live Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Swine Mycoplasma Hyopneumoniae Live Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Swine Mycoplasma Hyopneumoniae Live Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Swine Mycoplasma Hyopneumoniae Live Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Swine Mycoplasma Hyopneumoniae Live Vaccine market?
What factors are driving Swine Mycoplasma Hyopneumoniae Live Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Swine Mycoplasma Hyopneumoniae Live Vaccine market opportunities vary by end market size?
How does Swine Mycoplasma Hyopneumoniae Live Vaccine break out by Type, by Application?
Swine Mycoplasma Hyopneumoniae Live Vaccine is a preventive veterinary biological product formulated with live attenuated Mycoplasma hyopneumoniae strains, mainly used for the prevention of swine enzootic pneumonia, mycoplasmal pneumonia and related respiratory diseases in pigs. Commercial products are generally supplied as freeze-dried live vaccines, and the currently verifiable mainstream strain routes mainly include Strain 168 and Strain RM48, with administration routes such as intrapulmonary injection, intrathoracic injection and intranasal inoculation depending on product design. Upstream inputs mainly include production seed strains, specialized culture media, serum or serum substitutes, lyoprotectants, stabilizers, cultivation and harvesting consumables, vials or plastic bottles, rubber stoppers, aluminum caps, labels, cold-chain packaging materials and GMP-compliant biological manufacturing facilities. Downstream customers primarily include large-scale swine farming groups, breeding farms, commercial pig farms, veterinary drug distributors, animal disease prevention service providers and field veterinary service channels. Under a strict live-vaccine ex-factory scope, global effective production capacity in 2025 is estimated at about 218 million doses, with sales volume of about 151 million doses and an average ex-factory price of about USD 0.19 per dose. As commercialized supply is mainly concentrated in China, mainstream overseas Mycoplasma hyopneumoniae vaccines that are inactivated vaccines or combination vaccines are not included in this statistical scope. The industry gross margin in 2025 is estimated at around 45%?60%.
The current market is mainly centered on domestic production and application in China, and it remains a specialized segment within the veterinary vaccine industry. Supply is relatively concentrated, and demand mainly comes from large-scale pig farms, breeding farms and production systems with higher requirements for respiratory disease control. Compared with conventional inactivated vaccines, live vaccines place greater emphasis on respiratory local immunity and integrated herd-level disease prevention, giving them a stable application base in selected high-health-status farms.
Future development will focus more on administration convenience, product stability and adaptability to large-scale farming operations. As farming enterprises continue to pursue standardized vaccination programs, lower handling stress, reduced labor intensity and more consistent immune outcomes, products with easier administration, better field usability and stronger freeze-dried stability are expected to gain greater acceptance. Competition will increasingly depend on strain resources, manufacturing quality, field application evidence, technical service capability and farm-level solution design.
Market growth is mainly driven by the continued expansion of large-scale pig farming, stronger demand for integrated respiratory disease control, reduced antibiotic use and greater attention to production efficiency. Mycoplasma hyopneumoniae infection can interact with other pathogens and affect herd performance through coughing, lung lesions, slower growth and weaker feed conversion efficiency, so preventive vaccination remains an important part of stable pig production. When farm profitability improves and disease-control budgets recover, the penetration of this product category is expected to increase.
The main restraints include competition from substitute products, higher requirements for standardized use, hog cycle volatility and cost pressure at the farm level. Inactivated vaccines and combination vaccines have strong advantages in program integration, ease of use and channel coverage, so some farms may prefer simpler integrated immunization solutions. In addition, live vaccines require stricter cold-chain storage, reconstitution and administration practices, and improper execution may affect immune performance and repeat purchasing; during periods of weak hog prices, non-mandatory vaccine spending is also more likely to be reduced.
LP Information, Inc. (LPI) ' newest research report, the ?Swine Mycoplasma Hyopneumoniae Live Vaccine Industry Forecast? looks at past sales and reviews total world Swine Mycoplasma Hyopneumoniae Live Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Swine Mycoplasma Hyopneumoniae Live Vaccine sales for 2026 through 2032. With Swine Mycoplasma Hyopneumoniae Live Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Swine Mycoplasma Hyopneumoniae Live Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Swine Mycoplasma Hyopneumoniae Live Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Swine Mycoplasma Hyopneumoniae Live Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Swine Mycoplasma Hyopneumoniae Live Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Swine Mycoplasma Hyopneumoniae Live Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Swine Mycoplasma Hyopneumoniae Live Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Swine Mycoplasma Hyopneumoniae Live Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Strain 168 Live Vaccine
- Strain RM48 Live Vaccine
- Others
- Intrapulmonary Injection
- Intrathoracic Injection
- Others
- Small Pack (Below 20 Doses per Vial)
- Medium Pack (20?50 Doses per Vial)
- Large Pack (Above 50 Doses per Vial)
- Large-scale Pig Farming Groups
- Breeding Pig Farms
- Animal Health Service Providers
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Jofunhwa Group
- Qianyuanhao Biological
- Jilin Zhengye Biological Products
- Qilu Animal Health Products
- Shandong Lvdu Biotechnology
- Guangdong Wens Dahuanong Biotechnology
- Guangdong Winsun Bio-Pharmaceutical
- Harbin Pharmaceutical Group Bio-vaccine
- Wuhan Zhongbo Biotech
- China Animal Husbandry Industry
What is the 10-year outlook for the global Swine Mycoplasma Hyopneumoniae Live Vaccine market?
What factors are driving Swine Mycoplasma Hyopneumoniae Live Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Swine Mycoplasma Hyopneumoniae Live Vaccine market opportunities vary by end market size?
How does Swine Mycoplasma Hyopneumoniae Live Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Swine Mycoplasma Hyopneumoniae Live Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Swine Mycoplasma Hyopneumoniae Live Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Swine Mycoplasma Hyopneumoniae Live Vaccine Segment by Type
2.2.1 Strain 168 Live Vaccine
2.2.2 Strain RM48 Live Vaccine
2.2.3 Others
2.2.4 Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type
2.2.4.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Type (2021-2026)
2.2.4.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Type (2021-2026)
2.3 Swine Mycoplasma Hyopneumoniae Live Vaccine Segment by Administration Route
2.3.1 Intrapulmonary Injection
2.3.2 Intrathoracic Injection
2.3.3 Others
2.3.4 Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Administration Route
2.3.4.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Administration Route (2021-2026)
2.3.4.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue and Market Share by Administration Route (2021-2026)
2.3.4.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Administration Route (2021-2026)
2.4 Swine Mycoplasma Hyopneumoniae Live Vaccine Segment by Dose Pack Size
2.4.1 Small Pack (Below 20 Doses per Vial)
2.4.2 Medium Pack (20?50 Doses per Vial)
2.4.3 Large Pack (Above 50 Doses per Vial)
2.4.4 Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Dose Pack Size
2.4.4.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Dose Pack Size (2021-2026)
2.4.4.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue and Market Share by Dose Pack Size (2021-2026)
2.4.4.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Dose Pack Size (2021-2026)
2.5 Swine Mycoplasma Hyopneumoniae Live Vaccine Segment by Application
2.5.1 Large-scale Pig Farming Groups
2.5.2 Breeding Pig Farms
2.5.3 Animal Health Service Providers
2.5.4 Others
2.5.5 Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Application
2.5.5.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Market Share by Application (2021-2026)
2.5.5.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Breakdown Data by Company
3.1.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Company (2021-2026)
3.2.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Company
3.4 Key Manufacturers Swine Mycoplasma Hyopneumoniae Live Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Swine Mycoplasma Hyopneumoniae Live Vaccine Product Location Distribution
3.4.2 Players Swine Mycoplasma Hyopneumoniae Live Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SWINE MYCOPLASMA HYOPNEUMONIAE LIVE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Growth
4.4 APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Growth
4.5 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Growth
4.6 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Growth
5 AMERICAS
5.1 Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Country
5.1.1 Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Country (2021-2026)
5.1.2 Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Country (2021-2026)
5.2 Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type (2021-2026)
5.3 Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Region
6.1.1 APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Region (2021-2026)
6.1.2 APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Region (2021-2026)
6.2 APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type (2021-2026)
6.3 APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine by Country
7.1.1 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Country (2021-2026)
7.1.2 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Country (2021-2026)
7.2 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type (2021-2026)
7.3 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine by Country
8.1.1 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Swine Mycoplasma Hyopneumoniae Live Vaccine
10.3 Manufacturing Process Analysis of Swine Mycoplasma Hyopneumoniae Live Vaccine
10.4 Industry Chain Structure of Swine Mycoplasma Hyopneumoniae Live Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Swine Mycoplasma Hyopneumoniae Live Vaccine Distributors
11.3 Swine Mycoplasma Hyopneumoniae Live Vaccine Customer
12 WORLD FORECAST REVIEW FOR SWINE MYCOPLASMA HYOPNEUMONIAE LIVE VACCINE BY GEOGRAPHIC REGION
12.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size Forecast by Region
12.1.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Forecast by Region (2027-2032)
12.1.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Forecast by Type (2027-2032)
12.7 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Jofunhwa Group
13.1.1 Jofunhwa Group Company Information
13.1.2 Jofunhwa Group Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.1.3 Jofunhwa Group Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Jofunhwa Group Main Business Overview
13.1.5 Jofunhwa Group Latest Developments
13.2 Qianyuanhao Biological
13.2.1 Qianyuanhao Biological Company Information
13.2.2 Qianyuanhao Biological Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.2.3 Qianyuanhao Biological Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Qianyuanhao Biological Main Business Overview
13.2.5 Qianyuanhao Biological Latest Developments
13.3 Jilin Zhengye Biological Products
13.3.1 Jilin Zhengye Biological Products Company Information
13.3.2 Jilin Zhengye Biological Products Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.3.3 Jilin Zhengye Biological Products Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Jilin Zhengye Biological Products Main Business Overview
13.3.5 Jilin Zhengye Biological Products Latest Developments
13.4 Qilu Animal Health Products
13.4.1 Qilu Animal Health Products Company Information
13.4.2 Qilu Animal Health Products Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.4.3 Qilu Animal Health Products Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Qilu Animal Health Products Main Business Overview
13.4.5 Qilu Animal Health Products Latest Developments
13.5 Shandong Lvdu Biotechnology
13.5.1 Shandong Lvdu Biotechnology Company Information
13.5.2 Shandong Lvdu Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.5.3 Shandong Lvdu Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Shandong Lvdu Biotechnology Main Business Overview
13.5.5 Shandong Lvdu Biotechnology Latest Developments
13.6 Guangdong Wens Dahuanong Biotechnology
13.6.1 Guangdong Wens Dahuanong Biotechnology Company Information
13.6.2 Guangdong Wens Dahuanong Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.6.3 Guangdong Wens Dahuanong Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Guangdong Wens Dahuanong Biotechnology Main Business Overview
13.6.5 Guangdong Wens Dahuanong Biotechnology Latest Developments
13.7 Guangdong Winsun Bio-Pharmaceutical
13.7.1 Guangdong Winsun Bio-Pharmaceutical Company Information
13.7.2 Guangdong Winsun Bio-Pharmaceutical Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.7.3 Guangdong Winsun Bio-Pharmaceutical Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Guangdong Winsun Bio-Pharmaceutical Main Business Overview
13.7.5 Guangdong Winsun Bio-Pharmaceutical Latest Developments
13.8 Harbin Pharmaceutical Group Bio-vaccine
13.8.1 Harbin Pharmaceutical Group Bio-vaccine Company Information
13.8.2 Harbin Pharmaceutical Group Bio-vaccine Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.8.3 Harbin Pharmaceutical Group Bio-vaccine Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Harbin Pharmaceutical Group Bio-vaccine Main Business Overview
13.8.5 Harbin Pharmaceutical Group Bio-vaccine Latest Developments
13.9 Wuhan Zhongbo Biotech
13.9.1 Wuhan Zhongbo Biotech Company Information
13.9.2 Wuhan Zhongbo Biotech Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.9.3 Wuhan Zhongbo Biotech Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Wuhan Zhongbo Biotech Main Business Overview
13.9.5 Wuhan Zhongbo Biotech Latest Developments
13.10 China Animal Husbandry Industry
13.10.1 China Animal Husbandry Industry Company Information
13.10.2 China Animal Husbandry Industry Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.10.3 China Animal Husbandry Industry Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 China Animal Husbandry Industry Main Business Overview
13.10.5 China Animal Husbandry Industry Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Swine Mycoplasma Hyopneumoniae Live Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Swine Mycoplasma Hyopneumoniae Live Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Swine Mycoplasma Hyopneumoniae Live Vaccine Segment by Type
2.2.1 Strain 168 Live Vaccine
2.2.2 Strain RM48 Live Vaccine
2.2.3 Others
2.2.4 Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type
2.2.4.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Type (2021-2026)
2.2.4.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Type (2021-2026)
2.3 Swine Mycoplasma Hyopneumoniae Live Vaccine Segment by Administration Route
2.3.1 Intrapulmonary Injection
2.3.2 Intrathoracic Injection
2.3.3 Others
2.3.4 Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Administration Route
2.3.4.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Administration Route (2021-2026)
2.3.4.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue and Market Share by Administration Route (2021-2026)
2.3.4.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Administration Route (2021-2026)
2.4 Swine Mycoplasma Hyopneumoniae Live Vaccine Segment by Dose Pack Size
2.4.1 Small Pack (Below 20 Doses per Vial)
2.4.2 Medium Pack (20?50 Doses per Vial)
2.4.3 Large Pack (Above 50 Doses per Vial)
2.4.4 Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Dose Pack Size
2.4.4.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Dose Pack Size (2021-2026)
2.4.4.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue and Market Share by Dose Pack Size (2021-2026)
2.4.4.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Dose Pack Size (2021-2026)
2.5 Swine Mycoplasma Hyopneumoniae Live Vaccine Segment by Application
2.5.1 Large-scale Pig Farming Groups
2.5.2 Breeding Pig Farms
2.5.3 Animal Health Service Providers
2.5.4 Others
2.5.5 Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Application
2.5.5.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Market Share by Application (2021-2026)
2.5.5.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Breakdown Data by Company
3.1.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Company (2021-2026)
3.2.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Company
3.4 Key Manufacturers Swine Mycoplasma Hyopneumoniae Live Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Swine Mycoplasma Hyopneumoniae Live Vaccine Product Location Distribution
3.4.2 Players Swine Mycoplasma Hyopneumoniae Live Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SWINE MYCOPLASMA HYOPNEUMONIAE LIVE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Growth
4.4 APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Growth
4.5 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Growth
4.6 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Growth
5 AMERICAS
5.1 Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Country
5.1.1 Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Country (2021-2026)
5.1.2 Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Country (2021-2026)
5.2 Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type (2021-2026)
5.3 Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Region
6.1.1 APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Region (2021-2026)
6.1.2 APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Region (2021-2026)
6.2 APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type (2021-2026)
6.3 APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine by Country
7.1.1 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Country (2021-2026)
7.1.2 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Country (2021-2026)
7.2 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type (2021-2026)
7.3 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine by Country
8.1.1 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Swine Mycoplasma Hyopneumoniae Live Vaccine
10.3 Manufacturing Process Analysis of Swine Mycoplasma Hyopneumoniae Live Vaccine
10.4 Industry Chain Structure of Swine Mycoplasma Hyopneumoniae Live Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Swine Mycoplasma Hyopneumoniae Live Vaccine Distributors
11.3 Swine Mycoplasma Hyopneumoniae Live Vaccine Customer
12 WORLD FORECAST REVIEW FOR SWINE MYCOPLASMA HYOPNEUMONIAE LIVE VACCINE BY GEOGRAPHIC REGION
12.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size Forecast by Region
12.1.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Forecast by Region (2027-2032)
12.1.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Forecast by Type (2027-2032)
12.7 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Jofunhwa Group
13.1.1 Jofunhwa Group Company Information
13.1.2 Jofunhwa Group Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.1.3 Jofunhwa Group Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Jofunhwa Group Main Business Overview
13.1.5 Jofunhwa Group Latest Developments
13.2 Qianyuanhao Biological
13.2.1 Qianyuanhao Biological Company Information
13.2.2 Qianyuanhao Biological Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.2.3 Qianyuanhao Biological Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Qianyuanhao Biological Main Business Overview
13.2.5 Qianyuanhao Biological Latest Developments
13.3 Jilin Zhengye Biological Products
13.3.1 Jilin Zhengye Biological Products Company Information
13.3.2 Jilin Zhengye Biological Products Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.3.3 Jilin Zhengye Biological Products Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Jilin Zhengye Biological Products Main Business Overview
13.3.5 Jilin Zhengye Biological Products Latest Developments
13.4 Qilu Animal Health Products
13.4.1 Qilu Animal Health Products Company Information
13.4.2 Qilu Animal Health Products Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.4.3 Qilu Animal Health Products Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Qilu Animal Health Products Main Business Overview
13.4.5 Qilu Animal Health Products Latest Developments
13.5 Shandong Lvdu Biotechnology
13.5.1 Shandong Lvdu Biotechnology Company Information
13.5.2 Shandong Lvdu Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.5.3 Shandong Lvdu Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Shandong Lvdu Biotechnology Main Business Overview
13.5.5 Shandong Lvdu Biotechnology Latest Developments
13.6 Guangdong Wens Dahuanong Biotechnology
13.6.1 Guangdong Wens Dahuanong Biotechnology Company Information
13.6.2 Guangdong Wens Dahuanong Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.6.3 Guangdong Wens Dahuanong Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Guangdong Wens Dahuanong Biotechnology Main Business Overview
13.6.5 Guangdong Wens Dahuanong Biotechnology Latest Developments
13.7 Guangdong Winsun Bio-Pharmaceutical
13.7.1 Guangdong Winsun Bio-Pharmaceutical Company Information
13.7.2 Guangdong Winsun Bio-Pharmaceutical Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.7.3 Guangdong Winsun Bio-Pharmaceutical Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Guangdong Winsun Bio-Pharmaceutical Main Business Overview
13.7.5 Guangdong Winsun Bio-Pharmaceutical Latest Developments
13.8 Harbin Pharmaceutical Group Bio-vaccine
13.8.1 Harbin Pharmaceutical Group Bio-vaccine Company Information
13.8.2 Harbin Pharmaceutical Group Bio-vaccine Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.8.3 Harbin Pharmaceutical Group Bio-vaccine Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Harbin Pharmaceutical Group Bio-vaccine Main Business Overview
13.8.5 Harbin Pharmaceutical Group Bio-vaccine Latest Developments
13.9 Wuhan Zhongbo Biotech
13.9.1 Wuhan Zhongbo Biotech Company Information
13.9.2 Wuhan Zhongbo Biotech Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.9.3 Wuhan Zhongbo Biotech Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Wuhan Zhongbo Biotech Main Business Overview
13.9.5 Wuhan Zhongbo Biotech Latest Developments
13.10 China Animal Husbandry Industry
13.10.1 China Animal Husbandry Industry Company Information
13.10.2 China Animal Husbandry Industry Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
13.10.3 China Animal Husbandry Industry Swine Mycoplasma Hyopneumoniae Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 China Animal Husbandry Industry Main Business Overview
13.10.5 China Animal Husbandry Industry Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Strain 168 Live Vaccine
Table 4. Major Players of Strain RM48 Live Vaccine
Table 5. Major Players of Others
Table 6. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 7. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Type (2021-2026)
Table 8. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Type (2021-2026) & ($ million)
Table 9. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Type (2021-2026)
Table 10. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Type (2021-2026) & (US$/Dose)
Table 11. Major Players of Intrapulmonary Injection
Table 12. Major Players of Intrathoracic Injection
Table 13. Major Players of Others
Table 14. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Administration Route (2021-2026) & (K Dose)
Table 15. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Administration Route (2021-2026)
Table 16. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Administration Route (2021-2026) & ($ million)
Table 17. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Administration Route (2021-2026)
Table 18. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Administration Route (2021-2026) & (US$/Dose)
Table 19. Major Players of Small Pack (Below 20 Doses per Vial)
Table 20. Major Players of Medium Pack (20?50 Doses per Vial)
Table 21. Major Players of Large Pack (Above 50 Doses per Vial)
Table 22. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Dose Pack Size (2021-2026) & (K Dose)
Table 23. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Dose Pack Size (2021-2026)
Table 24. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Dose Pack Size (2021-2026) & ($ million)
Table 25. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Table 26. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Dose Pack Size (2021-2026) & (US$/Dose)
Table 27. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale by Application (2021-2026) & (K Dose)
Table 28. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Market Share by Application (2021-2026)
Table 29. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Application (2021-2026) & ($ million)
Table 30. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Application (2021-2026)
Table 31. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Application (2021-2026) & (US$/Dose)
Table 32. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Company (2021-2026) & (K Dose)
Table 33. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Company (2021-2026)
Table 34. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 35. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Company (2021-2026)
Table 36. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Company (2021-2026) & (US$/Dose)
Table 37. Key Manufacturers Swine Mycoplasma Hyopneumoniae Live Vaccine Producing Area Distribution and Sales Area
Table 38. Players Swine Mycoplasma Hyopneumoniae Live Vaccine Products Offered
Table 39. Swine Mycoplasma Hyopneumoniae Live Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 40. New Products and Potential Entrants
Table 41. Market M&A Activity & Strategy
Table 42. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Geographic Region (2021-2026) & (K Dose)
Table 43. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share Geographic Region (2021-2026)
Table 44. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 45. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 46. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Country/Region (2021-2026) & (K Dose)
Table 47. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Country/Region (2021-2026)
Table 48. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 49. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 50. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Country (2021-2026) & (K Dose)
Table 51. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Country (2021-2026)
Table 52. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 53. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 54. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 55. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Region (2021-2026) & (K Dose)
Table 56. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Region (2021-2026)
Table 57. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 58. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 59. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 60. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Country (2021-2026) & (K Dose)
Table 61. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 62. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 63. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 64. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Country (2021-2026) & (K Dose)
Table 65. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Country (2021-2026)
Table 66. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 67. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 68. Key Market Drivers & Growth Opportunities of Swine Mycoplasma Hyopneumoniae Live Vaccine
Table 69. Key Market Challenges & Risks of Swine Mycoplasma Hyopneumoniae Live Vaccine
Table 70. Key Industry Trends of Swine Mycoplasma Hyopneumoniae Live Vaccine
Table 71. Swine Mycoplasma Hyopneumoniae Live Vaccine Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. Swine Mycoplasma Hyopneumoniae Live Vaccine Distributors List
Table 74. Swine Mycoplasma Hyopneumoniae Live Vaccine Customer List
Table 75. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 76. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 77. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 78. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 79. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 80. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 82. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 84. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 85. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Forecast by Type (2027-2032) & (K Dose)
Table 86. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 87. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Forecast by Application (2027-2032) & (K Dose)
Table 88. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 89. Jofunhwa Group Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. Jofunhwa Group Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 91. Jofunhwa Group Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 92. Jofunhwa Group Main Business
Table 93. Jofunhwa Group Latest Developments
Table 94. Qianyuanhao Biological Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Qianyuanhao Biological Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 96. Qianyuanhao Biological Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 97. Qianyuanhao Biological Main Business
Table 98. Qianyuanhao Biological Latest Developments
Table 99. Jilin Zhengye Biological Products Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Jilin Zhengye Biological Products Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 101. Jilin Zhengye Biological Products Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 102. Jilin Zhengye Biological Products Main Business
Table 103. Jilin Zhengye Biological Products Latest Developments
Table 104. Qilu Animal Health Products Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Qilu Animal Health Products Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 106. Qilu Animal Health Products Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 107. Qilu Animal Health Products Main Business
Table 108. Qilu Animal Health Products Latest Developments
Table 109. Shandong Lvdu Biotechnology Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Shandong Lvdu Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 111. Shandong Lvdu Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 112. Shandong Lvdu Biotechnology Main Business
Table 113. Shandong Lvdu Biotechnology Latest Developments
Table 114. Guangdong Wens Dahuanong Biotechnology Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. Guangdong Wens Dahuanong Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 116. Guangdong Wens Dahuanong Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 117. Guangdong Wens Dahuanong Biotechnology Main Business
Table 118. Guangdong Wens Dahuanong Biotechnology Latest Developments
Table 119. Guangdong Winsun Bio-Pharmaceutical Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. Guangdong Winsun Bio-Pharmaceutical Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 121. Guangdong Winsun Bio-Pharmaceutical Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 122. Guangdong Winsun Bio-Pharmaceutical Main Business
Table 123. Guangdong Winsun Bio-Pharmaceutical Latest Developments
Table 124. Harbin Pharmaceutical Group Bio-vaccine Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 125. Harbin Pharmaceutical Group Bio-vaccine Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 126. Harbin Pharmaceutical Group Bio-vaccine Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 127. Harbin Pharmaceutical Group Bio-vaccine Main Business
Table 128. Harbin Pharmaceutical Group Bio-vaccine Latest Developments
Table 129. Wuhan Zhongbo Biotech Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 130. Wuhan Zhongbo Biotech Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 131. Wuhan Zhongbo Biotech Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 132. Wuhan Zhongbo Biotech Main Business
Table 133. Wuhan Zhongbo Biotech Latest Developments
Table 134. China Animal Husbandry Industry Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 135. China Animal Husbandry Industry Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 136. China Animal Husbandry Industry Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 137. China Animal Husbandry Industry Main Business
Table 138. China Animal Husbandry Industry Latest Developments
Table 1. Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Strain 168 Live Vaccine
Table 4. Major Players of Strain RM48 Live Vaccine
Table 5. Major Players of Others
Table 6. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 7. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Type (2021-2026)
Table 8. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Type (2021-2026) & ($ million)
Table 9. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Type (2021-2026)
Table 10. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Type (2021-2026) & (US$/Dose)
Table 11. Major Players of Intrapulmonary Injection
Table 12. Major Players of Intrathoracic Injection
Table 13. Major Players of Others
Table 14. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Administration Route (2021-2026) & (K Dose)
Table 15. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Administration Route (2021-2026)
Table 16. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Administration Route (2021-2026) & ($ million)
Table 17. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Administration Route (2021-2026)
Table 18. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Administration Route (2021-2026) & (US$/Dose)
Table 19. Major Players of Small Pack (Below 20 Doses per Vial)
Table 20. Major Players of Medium Pack (20?50 Doses per Vial)
Table 21. Major Players of Large Pack (Above 50 Doses per Vial)
Table 22. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Dose Pack Size (2021-2026) & (K Dose)
Table 23. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Dose Pack Size (2021-2026)
Table 24. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Dose Pack Size (2021-2026) & ($ million)
Table 25. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Table 26. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Dose Pack Size (2021-2026) & (US$/Dose)
Table 27. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale by Application (2021-2026) & (K Dose)
Table 28. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Market Share by Application (2021-2026)
Table 29. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Application (2021-2026) & ($ million)
Table 30. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Application (2021-2026)
Table 31. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Application (2021-2026) & (US$/Dose)
Table 32. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Company (2021-2026) & (K Dose)
Table 33. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Company (2021-2026)
Table 34. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 35. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Company (2021-2026)
Table 36. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Price by Company (2021-2026) & (US$/Dose)
Table 37. Key Manufacturers Swine Mycoplasma Hyopneumoniae Live Vaccine Producing Area Distribution and Sales Area
Table 38. Players Swine Mycoplasma Hyopneumoniae Live Vaccine Products Offered
Table 39. Swine Mycoplasma Hyopneumoniae Live Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 40. New Products and Potential Entrants
Table 41. Market M&A Activity & Strategy
Table 42. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Geographic Region (2021-2026) & (K Dose)
Table 43. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share Geographic Region (2021-2026)
Table 44. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 45. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 46. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Country/Region (2021-2026) & (K Dose)
Table 47. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Country/Region (2021-2026)
Table 48. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 49. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 50. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Country (2021-2026) & (K Dose)
Table 51. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Country (2021-2026)
Table 52. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 53. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 54. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 55. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Region (2021-2026) & (K Dose)
Table 56. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Region (2021-2026)
Table 57. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 58. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 59. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 60. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Country (2021-2026) & (K Dose)
Table 61. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 62. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 63. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 64. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Country (2021-2026) & (K Dose)
Table 65. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Country (2021-2026)
Table 66. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 67. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 68. Key Market Drivers & Growth Opportunities of Swine Mycoplasma Hyopneumoniae Live Vaccine
Table 69. Key Market Challenges & Risks of Swine Mycoplasma Hyopneumoniae Live Vaccine
Table 70. Key Industry Trends of Swine Mycoplasma Hyopneumoniae Live Vaccine
Table 71. Swine Mycoplasma Hyopneumoniae Live Vaccine Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. Swine Mycoplasma Hyopneumoniae Live Vaccine Distributors List
Table 74. Swine Mycoplasma Hyopneumoniae Live Vaccine Customer List
Table 75. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 76. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 77. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 78. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 79. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 80. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 82. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 84. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 85. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Forecast by Type (2027-2032) & (K Dose)
Table 86. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 87. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Forecast by Application (2027-2032) & (K Dose)
Table 88. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 89. Jofunhwa Group Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. Jofunhwa Group Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 91. Jofunhwa Group Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 92. Jofunhwa Group Main Business
Table 93. Jofunhwa Group Latest Developments
Table 94. Qianyuanhao Biological Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Qianyuanhao Biological Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 96. Qianyuanhao Biological Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 97. Qianyuanhao Biological Main Business
Table 98. Qianyuanhao Biological Latest Developments
Table 99. Jilin Zhengye Biological Products Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Jilin Zhengye Biological Products Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 101. Jilin Zhengye Biological Products Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 102. Jilin Zhengye Biological Products Main Business
Table 103. Jilin Zhengye Biological Products Latest Developments
Table 104. Qilu Animal Health Products Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Qilu Animal Health Products Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 106. Qilu Animal Health Products Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 107. Qilu Animal Health Products Main Business
Table 108. Qilu Animal Health Products Latest Developments
Table 109. Shandong Lvdu Biotechnology Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Shandong Lvdu Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 111. Shandong Lvdu Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 112. Shandong Lvdu Biotechnology Main Business
Table 113. Shandong Lvdu Biotechnology Latest Developments
Table 114. Guangdong Wens Dahuanong Biotechnology Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. Guangdong Wens Dahuanong Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 116. Guangdong Wens Dahuanong Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 117. Guangdong Wens Dahuanong Biotechnology Main Business
Table 118. Guangdong Wens Dahuanong Biotechnology Latest Developments
Table 119. Guangdong Winsun Bio-Pharmaceutical Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. Guangdong Winsun Bio-Pharmaceutical Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 121. Guangdong Winsun Bio-Pharmaceutical Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 122. Guangdong Winsun Bio-Pharmaceutical Main Business
Table 123. Guangdong Winsun Bio-Pharmaceutical Latest Developments
Table 124. Harbin Pharmaceutical Group Bio-vaccine Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 125. Harbin Pharmaceutical Group Bio-vaccine Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 126. Harbin Pharmaceutical Group Bio-vaccine Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 127. Harbin Pharmaceutical Group Bio-vaccine Main Business
Table 128. Harbin Pharmaceutical Group Bio-vaccine Latest Developments
Table 129. Wuhan Zhongbo Biotech Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 130. Wuhan Zhongbo Biotech Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 131. Wuhan Zhongbo Biotech Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 132. Wuhan Zhongbo Biotech Main Business
Table 133. Wuhan Zhongbo Biotech Latest Developments
Table 134. China Animal Husbandry Industry Basic Information, Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 135. China Animal Husbandry Industry Swine Mycoplasma Hyopneumoniae Live Vaccine Product Portfolios and Specifications
Table 136. China Animal Husbandry Industry Swine Mycoplasma Hyopneumoniae Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 137. China Animal Husbandry Industry Main Business
Table 138. China Animal Husbandry Industry Latest Developments
LIST OF FIGURES
Figure 1. Picture of Swine Mycoplasma Hyopneumoniae Live Vaccine
Figure 2. Swine Mycoplasma Hyopneumoniae Live Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Strain 168 Live Vaccine
Figure 12. Product Picture of Strain RM48 Live Vaccine
Figure 13. Product Picture of Others
Figure 14. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Type in 2026
Figure 15. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Type (2021-2026)
Figure 16. Product Picture of Intrapulmonary Injection
Figure 17. Product Picture of Intrathoracic Injection
Figure 18. Product Picture of Others
Figure 19. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Administration Route in 2026
Figure 20. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Administration Route (2021-2026)
Figure 21. Product Picture of Small Pack (Below 20 Doses per Vial)
Figure 22. Product Picture of Medium Pack (20?50 Doses per Vial)
Figure 23. Product Picture of Large Pack (Above 50 Doses per Vial)
Figure 24. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Dose Pack Size in 2026
Figure 25. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Figure 26. Swine Mycoplasma Hyopneumoniae Live Vaccine Consumed in Large-scale Pig Farming Groups
Figure 27. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Large-scale Pig Farming Groups (2021-2026) & (K Dose)
Figure 28. Swine Mycoplasma Hyopneumoniae Live Vaccine Consumed in Breeding Pig Farms
Figure 29. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Breeding Pig Farms (2021-2026) & (K Dose)
Figure 30. Swine Mycoplasma Hyopneumoniae Live Vaccine Consumed in Animal Health Service Providers
Figure 31. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Animal Health Service Providers (2021-2026) & (K Dose)
Figure 32. Swine Mycoplasma Hyopneumoniae Live Vaccine Consumed in Others
Figure 33. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Others (2021-2026) & (K Dose)
Figure 34. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Market Share by Application (2025)
Figure 35. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Application in 2025
Figure 36. Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Company in 2025 (K Dose)
Figure 37. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Company in 2025
Figure 38. Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Company in 2025 ($ millions)
Figure 39. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Company in 2025
Figure 40. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 41. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Geographic Region in 2025
Figure 42. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales 2021-2026 (K Dose)
Figure 43. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue 2021-2026 ($ millions)
Figure 44. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales 2021-2026 (K Dose)
Figure 45. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue 2021-2026 ($ millions)
Figure 46. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales 2021-2026 (K Dose)
Figure 47. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue 2021-2026 ($ millions)
Figure 48. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales 2021-2026 (K Dose)
Figure 49. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue 2021-2026 ($ millions)
Figure 50. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Country in 2025
Figure 51. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Country (2021-2026)
Figure 52. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Type (2021-2026)
Figure 53. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Application (2021-2026)
Figure 54. United States Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. Canada Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Mexico Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. Brazil Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Region in 2025
Figure 59. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Region (2021-2026)
Figure 60. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Type (2021-2026)
Figure 61. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Application (2021-2026)
Figure 62. China Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. Japan Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. South Korea Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Southeast Asia Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. India Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. Australia Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 68. China Taiwan Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Country in 2025
Figure 70. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Country (2021-2026)
Figure 71. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Type (2021-2026)
Figure 72. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Application (2021-2026)
Figure 73. Germany Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. France Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. UK Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 76. Italy Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 77. Russia Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 78. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Country (2021-2026)
Figure 79. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Type (2021-2026)
Figure 80. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Application (2021-2026)
Figure 81. Egypt Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 82. South Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 83. Israel Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 84. Turkey Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 85. GCC Countries Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 86. Manufacturing Cost Structure Analysis of Swine Mycoplasma Hyopneumoniae Live Vaccine in 2026
Figure 87. Manufacturing Process Analysis of Swine Mycoplasma Hyopneumoniae Live Vaccine
Figure 88. Industry Chain Structure of Swine Mycoplasma Hyopneumoniae Live Vaccine
Figure 89. Channels of Distribution
Figure 90. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Forecast by Region (2027-2032)
Figure 91. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 92. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 93. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 94. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 95. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Swine Mycoplasma Hyopneumoniae Live Vaccine
Figure 2. Swine Mycoplasma Hyopneumoniae Live Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Strain 168 Live Vaccine
Figure 12. Product Picture of Strain RM48 Live Vaccine
Figure 13. Product Picture of Others
Figure 14. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Type in 2026
Figure 15. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Type (2021-2026)
Figure 16. Product Picture of Intrapulmonary Injection
Figure 17. Product Picture of Intrathoracic Injection
Figure 18. Product Picture of Others
Figure 19. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Administration Route in 2026
Figure 20. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Administration Route (2021-2026)
Figure 21. Product Picture of Small Pack (Below 20 Doses per Vial)
Figure 22. Product Picture of Medium Pack (20?50 Doses per Vial)
Figure 23. Product Picture of Large Pack (Above 50 Doses per Vial)
Figure 24. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Dose Pack Size in 2026
Figure 25. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Figure 26. Swine Mycoplasma Hyopneumoniae Live Vaccine Consumed in Large-scale Pig Farming Groups
Figure 27. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Large-scale Pig Farming Groups (2021-2026) & (K Dose)
Figure 28. Swine Mycoplasma Hyopneumoniae Live Vaccine Consumed in Breeding Pig Farms
Figure 29. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Breeding Pig Farms (2021-2026) & (K Dose)
Figure 30. Swine Mycoplasma Hyopneumoniae Live Vaccine Consumed in Animal Health Service Providers
Figure 31. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Animal Health Service Providers (2021-2026) & (K Dose)
Figure 32. Swine Mycoplasma Hyopneumoniae Live Vaccine Consumed in Others
Figure 33. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Others (2021-2026) & (K Dose)
Figure 34. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sale Market Share by Application (2025)
Figure 35. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Application in 2025
Figure 36. Swine Mycoplasma Hyopneumoniae Live Vaccine Sales by Company in 2025 (K Dose)
Figure 37. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Company in 2025
Figure 38. Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Company in 2025 ($ millions)
Figure 39. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Company in 2025
Figure 40. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 41. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Geographic Region in 2025
Figure 42. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales 2021-2026 (K Dose)
Figure 43. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue 2021-2026 ($ millions)
Figure 44. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales 2021-2026 (K Dose)
Figure 45. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue 2021-2026 ($ millions)
Figure 46. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales 2021-2026 (K Dose)
Figure 47. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue 2021-2026 ($ millions)
Figure 48. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales 2021-2026 (K Dose)
Figure 49. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue 2021-2026 ($ millions)
Figure 50. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Country in 2025
Figure 51. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Country (2021-2026)
Figure 52. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Type (2021-2026)
Figure 53. Americas Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Application (2021-2026)
Figure 54. United States Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. Canada Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Mexico Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. Brazil Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Region in 2025
Figure 59. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Region (2021-2026)
Figure 60. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Type (2021-2026)
Figure 61. APAC Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Application (2021-2026)
Figure 62. China Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. Japan Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. South Korea Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Southeast Asia Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. India Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. Australia Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 68. China Taiwan Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Country in 2025
Figure 70. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Country (2021-2026)
Figure 71. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Type (2021-2026)
Figure 72. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Application (2021-2026)
Figure 73. Germany Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. France Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. UK Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 76. Italy Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 77. Russia Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 78. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Country (2021-2026)
Figure 79. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Type (2021-2026)
Figure 80. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share by Application (2021-2026)
Figure 81. Egypt Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 82. South Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 83. Israel Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 84. Turkey Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 85. GCC Countries Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 86. Manufacturing Cost Structure Analysis of Swine Mycoplasma Hyopneumoniae Live Vaccine in 2026
Figure 87. Manufacturing Process Analysis of Swine Mycoplasma Hyopneumoniae Live Vaccine
Figure 88. Industry Chain Structure of Swine Mycoplasma Hyopneumoniae Live Vaccine
Figure 89. Channels of Distribution
Figure 90. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Forecast by Region (2027-2032)
Figure 91. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 92. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 93. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 94. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 95. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share Forecast by Application (2027-2032)
